Hematologic Complications of Immune Checkpoint Inhibitors

Immune checkpoint inhibitors have improved outcomes for patients with numerous hematological and solid cancers. Hematologic toxicities have been described, but the spectrum, timing, and clinical presentation of these complications are not well understood. We used the World Health Organization's...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Elizabeth J., Salem, Joe‐Elie, Young, Arissa, Green, Jennifer R., Ferrell, P. Brent, Ancell, Kristin K., Lebrun‐Vignes, Benedicte, Moslehi, Javid J., Johnson, Douglas B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Immune‐Related Adverse Events
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516131/
https://www.ncbi.nlm.nih.gov/pubmed/30819785
http://dx.doi.org/10.1634/theoncologist.2018-0574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516131/
https://www.ncbi.nlm.nih.gov/pubmed/30819785
http://dx.doi.org/10.1634/theoncologist.2018-0574

Ejemplares similares